Journals / Glokom Katarakt / 2012 / Cilt: 7 - Sayı: 2

The clinical use of tissue plasminogen activator for fibrin membrane after cataract surgery

Katarakt ameliyatı sonrası fibrin membran tedavisinde doku plazminojen aktivatörünün klinik kullanımı

Pages
109–112
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Low dose intracameral tPA is an effective and safe method for persistent fibrin membrane formation following cataract surgery.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the efficiency of the use of intracameral tissue plasminogen activator (tPA) for severe anterior segment fibrin membrane formation following uneventful cataract surgery that fails to respond to maximum topical and systemic anti-inflammatory therapy.
📊
Key Findings & Data:Material and Methods: 0.1 cc of 25 μg/ml tPA was applied to the anterior chamber in 20 patients who had fibrin membrane formation following uneventful cataract surgery that failed to respond to maximal anti-inflammatory treatment.
💡
Conclusion & Impact:Conclusion: Low dose intracameral tPA is an effective and safe method for persistent fibrin membrane formation following cataract surgery.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the efficiency of the use of intracameral tissue plasminogen activator (tPA) for severe anterior segment fibrin membrane formation following uneventful cataract surgery that fails to respond to maximum topical and systemic anti-inflammatory therapy. Material and Methods: 0.1 cc of 25 μg/ml tPA was applied to the anterior chamber in 20 patients who had fibrin membrane formation following uneventful cataract surgery that failed to respond to maximal anti-inflammatory treatment. The intervention is done in the 8th to 30th postoperative days. The dissolution of fibrin membrane, visual acuity and intraocular pressures were assessed on 1., 2., 3. hours, 1., 2., 3., days and 1., 2., 3. weeks following the tPA injection. Results: After intracameral tPA application, 12 cases out of 20 (60%) showed complete dissolution of the fibrin membrane. 6 cases (30%) had a partial improvement and these cases had complete resolution with additional anti-inflammatory therapy. 1 case (5%) showed no improvement while another case (5%) had complete resolution after a second tPA application. In 3 cases that had angle closure with pupillary block, intraocular pressure dropped to normal levels one day after tPA. Visual acuity improved in 12 cases (60%) on whom tPA was effective and in 1 additional case (5%) that had tPA re-application. In one case that was resistant to tPA, intraocular pressure following tPA had a transient increase that had responded to anti-glaucomatous therapy. Conclusion: Low dose intracameral tPA is an effective and safe method for persistent fibrin membrane formation following cataract surgery.

Özet

Amaç: Komplikasyonsuz katarakt cerrahisi sonrası maksimum topikal ve sistemik antiinflamatuar tedaviye cevap vermeyen ciddi ön segment fibrin membran reaksiyonlarında ön kamaraya verilen doku plazminojen aktivatörünün (tPA) etkinliğini araştırmak. Gereç ve Yöntemler: Komplikasyonsuz katarakt cerrahisi sonrası fibrin membran reaksiyonu olan ve maksimum antiinflamatuar tedaviye cevap vermeyen 20 olguda ön kamaraya 25 μg/ml 0.1 cc tPA uygulandı. Uygulama 8-30. günler arasında yapıldı. tPA enjeksiyonu sonrası topikal kortikosteroid ve sikloplejik tedaviye devam edildi. Olgular enjeksiyon sonrası 1., 2. ,3. saatte, 1., 2., 3. günde ve 1. ,2. ,3. ,4. haftalarda fibrin membranda çözülme, görme keskinliği ve göz içi basıncı yönünden değerlendirildi. Bulgular: Ön kamaraya tPA uygulanması sonucunda 20 olgunun 12'sinde (%60) fibrin membranda tam düzelme, 6'sında (%30) kısmi düzelme oldu. Kısmi düzelme olan olgularda 1 hafta ek antiinflamatuar tedaviyle tam düzelme gerçekleşti. Enjeksiyon sonrası kısmi düzelme olan 1 olguda (%5) 2. tPA uygulanması sonrası tam düzelme olurken, 1 olguda (%5) herhangi bir düzelme saptanmadı. Pupiller blok ile açı kapanması gelişmiş olan 3 olguda tPA sonrası oluşan fibrinolizisle birlikte göz içi basınçları enjeksiyonun ilk gününde normal düzeye indi. tPA'nın etkin olduğu 12 olgu (%60) ve tekrar tPA uygulanan 1 olguda (%5) görme düzeylerinde artış oldu. tPA'nın etkin olmadığı 1 olguda tPA sonrası medikal antiglokomatöz tedaviye cevap veren geçici göz içi basınç artışı oldu. Sonuç: Ön kamaraya düşük doz tPA verilmesi katarakt cerrahisi sonrası oluşan persistan fibrin membran tedavisinde etkin ve güvenilir bir yöntemdir.

🔖

Cite This Article

BAŞARIR, B., EREN, H., PINARCI, E. Y., ALTAN, Ç., MERT, S., DEMİROK, A., KAPRAN, Z., YILMAZ, Ö. F. (2012). The clinical use of tissue plasminogen activator for fibrin membrane after cataract surgery. Glokom Katarakt, Cilt: 7 - Sayı: 2, 109–112. https://ajindex.com/articles/216186

References (15)

  1. Miyake K, Maekubo K, Miyake Y, et al. Pupillary fibrin mem brane. A frequent early complication after posterior chamber lens implantation in Japan. Ophthalmology 1989;96:1228-33
  2. Menapace R, Amon M, Radax U. Evaluation of 200 consecu tive IOGEL 1103 capsuler-bag lenses implanted through a small incision. J Cataract Refract Surg 1992;18:252-64
  3. Zetterström C, Olivestedt G, Lunvall A. Exfoliation syndrome and extracapsular cataract extraction with implantation of posterior chamber lens. Acta Opthalmol 1992;70:85-90
  4. Wedrich A, Menapace R, Radax U,et al. Long-term results of combined trabeculectomy and small incision cataract surgery. J Cataract Refract Surg 1995;21:49-54
  5. Willams GA, Lambrou FH, Jaffe GA. Treatment of postvit rectomy fibrin formation with intraocular tissue plasminogen activator. Arch Ophthalmol 1988;106:1055-8
  6. Wedrich A, Menapace R, Ries E, et al. Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery. J Cataract Refract Surg 1997;23:873-7
  7. Giedrojc J, Stankiewicz A, Walkowiak M. Tissue plasminogen activator and plasminogen activator inhibitor in aqueous hu mor of the human eye. Klin Oczna 1996;98:283-5
  8. Özveren F, Eltutar K. Therapeutic application of tissue plas minogen activator for fibrin reaction after cataract surgery. J Cataract Refract Surg 2004;30:1727-31
  9. Georgiadis N, Boboridis K, Halvatzis N. Low-dose tissue plas minogen activator in the management of anterior chamber fibrin formation. J Cataract Refract Surg 2003;29:729-32
  10. Lundy D, Sidoti P, Winarko T. Intracameral tissue plas minogen activator after glaucoma surgery. Ophhthalmology 1996;103:274-82
  11. Erol N, Ozer A, Topbas S, et al. Treatment of intracameral fi brinous membranees with tissue plasminogen activator. Oph thalmic Surg Lasers Imaging 2003;34:451-6
  12. Zalta A, Sweeney C, Zalta A, et al. Intracameral tissue plas minogen activator use in a large series of eyes with valved glau coma drainage implants. Arch Ophthalmol 2002;120:1487-93
  13. Yoshino H, Seki M, Ueda J, et al. Fibrin membranee pupil lary-block glaucoma after uneventful cataract surgery treated with intracameral tissue plasminogen activator: a case report. BMC Ophthalmol 2012;20;12:3
  14. Wu TT, Wang HH. Intracameral recombinant tissue plasmin ogen activator for the treatment of severe fibrin reaction in endophthalmitis. Eye 2009;23:101-7
  15. Siatiri H, Beheshtnezhad AH, Asghari H, et al. Intracam eral tissue plasminogen activ